Bridgeway Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Bridgeway Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-107,700	Closed	-$274K	–	1473
2023 Q1	$274K	Sell	107,700 -115,000	-52%	-$227K	0.01%	1040
2022 Q4	$416K	Buy	222,700 +100,000	+81%	+$249K	0.01%	925
2022 Q3	$315K	Hold	122,700	–	–	0.01%	1021
2022 Q2	$237K	Hold	122,700	–	–	0.01%	1053
2022 Q1	$364K	Sell	122,700 -35,000	-22%	-$132K	0.01%	1018
2021 Q4	$708K	Buy	+157,700	New	+$748K	0.01%	878
2020 Q2	–	Sell	-151,800	Closed	-$478K	–	1420
2020 Q1	$478K	Buy	151,800 +50,000	+49%	+$184K	0.01%	778
2019 Q4	$410K	Buy	101,800 +6,800	+7%	+$23.6K	0.01%	1054
2019 Q3	$410K	Hold	95,000	–	–	0.01%	1025
2019 Q2	$379K	Buy	+95,000	New	+$452K	﹤0.01%	1045
2014 Q4	–	Sell	-5,583	Closed	-$136K	–	1528
2014 Q3	$136K	Sell	5,583 -5,834	-51%	-$152K	﹤0.01%	1386
2014 Q2	$273K	Hold	11,417	–	–	0.01%	1273
2014 Q1	$422K	Buy	11,417 +5,834	+104%	+$230K	0.01%	1149
2013 Q4	$225K	Hold	5,583	–	–	0.01%	1283
2013 Q3	$213K	Buy	+5,583	New	+$200K	0.01%	1301

Other funds holding PRTK

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Bridgeway Capital Management's PRTK Position: Q2 2023 in Review

Bridgeway Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2023, closing a stake of 107,700 shares — an estimated $274K sold.

Bridgeway Capital Management first reported a position in PRTK in Q3 2013 and held it in 15 quarters. The position peaked at $708K in Q4 2021. 66 funds tracked by Wall St. Rank hold PRTK as of Q2 2023.

Bridgeway Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Bridgeway Capital Management sold 107,700 Paratek Pharmaceuticals, Inc. shares in Q2 2023, an estimated $274K.
Bridgeway Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2013 and held it in 15 quarters.
Bridgeway Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $708K in Q4 2021.
66 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2023.

Based on Bridgeway Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.